Opioid Receptor Pharmacology and Therapeutics

Opioid receptors are a subclass of G protein-coupled receptors comprising mu (MOR), kappa (KOR) and delta (DOR) subtypes that orchestrate the effects of both endogenous peptides and therapeutic opioids. Activation of these receptors triggers G protein signalling cascades that underlie analgesia, mood regulation and autonomic control. Concomitantly, receptor phosphorylation and recruitment of β-arrestins influence desensitisation, internalisation and biased signalling, yielding distinct functional outcomes. Biased agonism—where ligands preferentially engage either G protein or arrestin pathways—has emerged as a strategy to enhance analgesia while reducing tolerance, respiratory depression and dependence. Structural elucidation of active receptor states and the advent of genetically encoded biosensors have transformed our ability to monitor opioid peptide dynamics in real time and to design ligands with tailored efficacy profiles. Beyond classical agonists, novel therapeutic approaches encompass peripheral-restricted molecules, multifunctional ligands targeting receptor heteromers or splice variants, and gene-based augmentation of endogenous opioid production. These advances hold promise for global pain management and for mitigating the public health challenges of opioid misuse by fostering safer, more effective analgesics.

Research from Nature Portfolio

Recent studies have introduced fluorescent biosensors specific for μ, κ and δ receptors, enabling high-resolution mapping of endogenous opioid release in brain slices and in vivo under rewarding and aversive conditions. Structural analyses of KOR bound to G protein- and arrestin-biased agonists have elucidated distinct active-state conformations, revealing molecular determinants that govern signalling bias and informing design of next-generation analgesics. Moreover, genetically engineered phosphorylation-deficient MORs in knockin mice demonstrate that G protein-biased signalling amplifies analgesia and attenuates tolerance, yet does not alleviate side effects such as respiratory depression, emphasising the complexity of receptor regulation in vivo.

Opioid Receptor Pharmacology and Therapeutics publication trend

The graph below shows the total number of articles in opioid receptor pharmacology and therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

G protein-coupled receptor (GPCR): A membrane protein that transduces extracellular signals into intracellular responses via heterotrimeric G proteins.

Biased agonism: The property of a ligand to preferentially activate specific downstream signalling pathways of a receptor.

β-arrestin: An adaptor protein that binds phosphorylated GPCRs, desensitising G protein signalling and mediating receptor internalisation.

Phosphorylation: The enzymatic addition of phosphate groups to amino acid residues, modulating protein function and signalling.

Nanobody: A single-domain antibody fragment used to stabilise specific protein conformations for structural studies.

Genetically encoded biosensor: An engineered protein that reports molecular interactions or signalling events through fluorescence changes in living cells.

References

1. Unlocking opioid neuropeptide dynamics with genetically encoded biosensors. Nature Neuroscience (2024).
2. Molecular mechanism of biased signaling at the kappa opioid receptor. Nature Communications (2023).
3. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell (2018).
4. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature Communications (2019).
5. Morphine‐induced respiratory depression is independent of β‐arrestin2 signalling. British Journal of Pharmacology (2020).
6. The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. British Journal of Pharmacology (2018).